This uniquely consummate combination therapy involving the genetic approach using shRNA technology to knockdown the expression of LC3 along with the pharmacological intervention using the anti-cancer isoflavone GST was highly effective in controlling the growth of human malignant neuroblastoma cells in culture and animal models. Here, MAP1LC3A is linked to cancer.